Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;11(6):1420-1429.
doi: 10.1002/acn3.52040. Epub 2024 May 8.

Mitochondrial dysfunction in brain tissues and Extracellular Vesicles Fragile X-associated tremor/ataxia syndrome

Affiliations

Mitochondrial dysfunction in brain tissues and Extracellular Vesicles Fragile X-associated tremor/ataxia syndrome

Pamela J Yao et al. Ann Clin Transl Neurol. 2024 Jun.

Abstract

Objective: Mitochondrial impairments have been implicated in the pathogenesis of Fragile X-associated tremor/ataxia syndrome (FXTAS) based on analysis of mitochondria in peripheral tissues and cultured cells. We sought to assess whether mitochondrial abnormalities present in postmortem brain tissues of patients with FXTAS are also present in plasma neuron-derived extracellular vesicles (NDEVs) from living carriers of fragile X messenger ribonucleoprotein1 (FMR1) gene premutations at an early asymptomatic stage of the disease continuum.

Methods: We utilized postmortem frozen cerebellar and frontal cortex samples from a cohort of eight patients with FXTAS and nine controls and measured the quantity and activity of the mitochondrial proteins complex IV and complex V. In addition, we evaluated the same measures in isolated plasma NDEVs by selective immunoaffinity capture targeting L1CAM from a separate cohort of eight FMR1 premutation carriers and four age-matched controls.

Results: Lower complex IV and V quantity and activity were observed in the cerebellum of FXTAS patients compared to controls, without any differences in total mitochondrial content. No patient-control differences were observed in the frontal cortex. In NDEVs, FMR1 premutation carriers compared to controls had lower activity of Complex IV and Complex V, but higher Complex V quantity.

Interpretation: Quantitative and functional abnormalities in mitochondrial electron transport chain complexes IV and V seen in the cerebellum of patients with FXTAS are also manifest in plasma NDEVs of FMR1 premutation carriers. Plasma NDEVs may provide further insights into mitochondrial pathologies in this syndrome and could potentially lead to the development of biomarkers for predicting symptomatic FXTAS among premutation carriers and disease monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests to declare.

Figures

Figure 1
Figure 1
Analysis of postmortem brain tissues of patients with FXTAS. (A, B) Comparison of the mean quantity and activity of mitochondrial complex IV in the frontal cortex (A) and cerebellum (B) of patients with FXTAS and controls. (C, D) Comparison of the mean quantity and activity of mitochondrial complex V in the frontal cortex (C) and cerebellum (D) of patients with FXTAS and controls. (E) Total mitochondrial contents in tissue lysates (20 μg of total protein) of patients with FXTAS and controls were determined using a mitochondrial membrane‐specific dye MTDR. (F) (top) Immunoblots of mitochondrial citrate synthase and Actin in cerebellum tissues; (bottom) Histogram of citrate synthase levels (normalized to Actin of the same sample) in the cerebellum of seven patients with FXTAS (f1‐7) and seven controls (c1‐7). Values in (A–D) were normalized by mitochondrial content of each tissue sample. Shown in each bar is mean ± SEM. Each diamond represents data from one subject (frontal cortex, n = 8 for patients with FXTAS, n = 7 for controls; cerebellum, n = 8 for patients with FXTAS, n = 9 for controls). p values were calculated using Mann–Whitney U tests for mitochondrial contents and linear mixed models for mitochondrial measures. AU, arbitrary units; CS, citrate synthase; FXTAS, Fragile X‐associated tremor/ataxia syndrome; MTDR, MitoTracker Deep Red; RFU, relative fluorescence units; *p < 0.05; **p < 0.01.
Figure 2
Figure 2
Analysis of mitochondrial complex I‐ and complex II‐mediated respiration in brain tissues of patients with FXTAS. (A) Example traces of NADH‐induced respiration representing Complex I‐mediated OCR of frozen frontal cortex and cerebellum homogenates from control subjects. (B) Comparison of Complex I‐mediated OCR in the frontal cortex and cerebellar tissues from patients with FXTAS and controls. (C) Example traces of succinate‐induced respiration representing Complex II‐mediated OCR of frozen frontal cortex and cerebellum homogenates from control subjects. (D) Comparison of Complex II‐mediated OCR in the frontal cortex and cerebellar tissues from patients with FXTAS and controls. In (B) and (D), shown in each bar is mean ± SEM. Each diamond represents data from one subject (frontal cortex, n = 8 for patients with FXTAS, n = 7 for controls; cerebellum, n = 8 for patients with FXTAS, n = 9 for controls). Analysis was performed by fitting linear mixed models. AA, antimycin A; Asc, ascorbic acid; Cb, cerebellum; Fc, frontal cortex; FXTAS, Fragile X‐associated tremor/ataxia syndrome; NADH, nicotinamide adenine dinucleotide hydrogen; OCR, oxygen consumption rate; TMPD, tetramethyl‐p‐phenylenediamine dihydrochloride.
Figure 3
Figure 3
Analysis of plasma NDEVs of premutation (PM) carriers. (A) Comparison of the mean quantity and activity of mitochondrial respiratory chain complex IV in NDEVs of PM carriers and control subjects. (B) Comparison of the mean quantity and activity of mitochondrial respiratory chain complex V in NDEVs of PM carriers and control subjects. (C) Comparison of the concentration (particles/μL) and average diameter of NDEVs between PM carriers and control subjects. Shown in each bar is mean ± SEM. Each diamond represents data from one subject (n = 8 for PM carriers, n = 4 for control subjects). p values were calculated using Mann–Whitney U tests for NDEV characteristics and a general linear model for mitochondrial measures. AU, arbitrary units; PM, premutation; *p < 0.05.

Similar articles

References

    1. Bourgeois JA, Cogswell JB, Hessl D, et al. Cognitive, anxiety and mood disorders in the fragile X‐associated tremor/ataxia syndrome. Gen Hosp Psychiatry. 2007;29(4):349‐356. - PMC - PubMed
    1. Filley CM, Brown MS, Onderko K, et al. White matter disease and cognitive impairment in FMR1 premutation carriers. Neurology. 2015;84(21):2146‐2152. - PMC - PubMed
    1. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57(1):127‐130. - PubMed
    1. Salcedo‐Arellano MJ, Wolf‐Ochoa MW, Hong T, et al. Parkinsonism versus concomitant Parkinson's disease in fragile X‐associated tremor/ataxia syndrome. Mov Disord Clin Pract. 2020;7(4):413‐418. - PMC - PubMed
    1. Hagerman RJ, Hagerman P. Fragile X‐associated tremor/ataxia syndrome ‐ features, mechanisms and management. Nat Rev Neurol. 2016;12(7):403‐412. - PubMed

MeSH terms

Substances

Supplementary concepts